XOMA Corp. (XOMA)

26.38
0.58 2.20
NASDAQ : Health Technology
Prev Close 25.80
Open 25.88
Day Low/High 25.53 / 26.79
52 Wk Low/High 4.50 / 37.25
Volume 32.44K
Avg Volume 176.30K
Exchange NASDAQ
Shares Outstanding 8.14M
Market Cap 210.93M
EPS -8.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABAX, ATKR, AUTO, BIO.B, BWINB, CNCE, EGY, NWS, RADA, RFP, SBNY, SORL, WDAY, XOMA Downgrades: ATRC, CCR, GPRK, GWRE, HCAP, KODK, SNPS Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

XOMA Announces Multiple New License Agreements For Proprietary Phage Display Libraries

XOMA Announces Multiple New License Agreements For Proprietary Phage Display Libraries

Expands portfolio of partner-funded programs with potential for milestone and royalty payments

XOMA Announces Positive Results From Its Phase 2 Proof-Of-Concept Study Of Prolactin Inhibition

X213 shown to be safe and effective, demonstrating complete suppression of lactation in study participants

XOMA Presents Positive Data From PTH1R Monoclonal Antibody Program

Unmet medical needs in parathyroid hormone-related hypercalcemia contribute to potential partnering value of overall portfolio

XOMA Announces Four Presentations At The 2017 ENDO Meeting

Oral and Poster Presentations to Highlight Preclinical and Clinical Program Advances for Hypoglycemia and Hypercalcemia

XOMA Announces Full Repayment Of Hercules Technology Growth Capital Debt Obligation

Company extinguishes Hercules term loan; repayment further reduces operating expenses and strengthens XOMA's balance sheet, reflecting its new business strategy

XOMA Appoints Matthew Perry To Its Board Of Directors

Company outlines new strategic imperatives and value drivers

XOMA Establishes Proof-of-Concept For 358 In Congenital Hyperinsulinism And Hypoglycemia Post-Bariatric Surgery

Congenital Hyperinsulinism Phase 2 study completed and multi-dose study protocol approved in the United Kingdom; Company initiates multi-dose study in hypoglycemic Post-Bariatric Surgery patients

TheStreet Quant Rating: C- (Hold)